Financial Performance - Q4 2017 - Revenue increased by 5.6% [15] - Gross Profit margin increased from 55.3% to 57.5% [15] - Adjusted EPS increased by 5.8% to $3.48 [15] Fiscal Year 2018 Outlook - Pro forma revenue is expected to be between $3,645 million and $3,725 million [13] - GAAP net income is projected to be between 25% and 28% [13] - The company anticipates net income between $702 million and $738 million [13] - GAAP EPS is expected to be between $11.61 and $12.25 [13] Liquidity and Debt - Net cash provided by operating activities was $788.7 million [16] - Capital expenditures totaled $71 million [16] - Free cash flow reached $717.7 million [16] - The company's net debt to EBITDA As Defined multiple was 3.9x [17]

Financial Performance - Apogee's Q1 FY26 net sales reached $346.6 million, a 4.6% year-over-year increase[13, 14] - Adjusted EBITDA was $34.4 million, a 34.7% decrease year-over-year[13, 14] - Adjusted EBITDA margin was 9.9%, a 600 bps decrease year-over-year[13, 14] - Adjusted diluted EPS was $0.56, a 61.1% decrease year-over-year[13, 14] Segment Results - Architectural Metals net sales were $128.6 million, a 3.4% decrease year-over-year, with an adjusted EBITDA margin of 7.3%, a 1060 bps decrease[21, 24] - Architectural Services net sales were $106.5 million, a 7.6% increase year-over-year, with an adjusted EBITDA margin of 5.7%, a 90 bps decrease[21, 24] - Architectural Glass net sales were $73.3 million, a 15.5% decrease year-over-year, with an adjusted EBITDA margin of 18.3%, a 500 bps decrease[21, 24] - Performance Surfaces net sales were $42.3 million, a 99.3% increase year-over-year, with an adjusted EBITDA margin of 18.8%, a 780 bps decrease[21, 24] FY26 Outlook - The company is increasing its full-year FY26 outlook for net sales to $1.40 billion - $1.44 billion[39] - The company is increasing its full-year FY26 outlook for adjusted diluted EPS to $3.80 to $4.20[39]

Strategic Partnerships & Financial Restructuring - Amarin has entered into an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in 59 countries, primarily in Europe[13] - The Recordati agreement includes $25 million in upfront cash[9] and up to $150 million in milestone payments based on net sales levels[9] - Global restructuring is expected to generate approximately $70 million in cost savings over the next 12 months[6, 16, 24] VAZKEPA/VAZKEPA Market & Growth - VAZKEPA has CVRR indication regulatory approvals in 49 global markets[7] - Demand for VASCEPA/VAZKEPA has grown by 77% in aggregate, comparing Q1 2025 to Q1 2024[22] - The company maintains over 40% share of the IPE market in the U S [21] US Market & Global Expansion - The refined commercial strategy in the U S focuses on payer coverage post-loss of exclusivity[21] - Partnerships in Rest of World are focused on maximizing patient access to VASCEPA globally, with commercialization across 11 countries and regulatory submissions pending in 8 additional markets[23]

Efficacy of MariTide - MariTide demonstrated strong efficacy with up to approximately 20% average weight loss without a plateau at 52 weeks[9, 84] - Up to approximately 98% of patients without Type 2 diabetes lost ≥5% of their body weight[29] - Up to approximately 99% of patients with Type 2 diabetes lost ≥ 5% of their body weight[38] - In adults with obesity WITH Type 2 Diabetes, MariTide demonstrated an impressive up to approximately 17% average weight loss at 52 weeks without a weight loss plateau[35] Cardiometabolic Improvements - In adults with obesity WITH Type 2 Diabetes, MariTide 420 mg monthly resulted in a -22% change in HbA1c, -58 mg/dL in Glucose, -11 mmHg in Systolic blood pressure, -28% in Triglycerides, and -72% in hs-CRP from baseline to week 52[41] - In adults with obesity WITHOUT Type 2 Diabetes, pooled 420 MariTide dose arms resulted in - 11 mmHg in Systolic blood pressure, - 5% in LDL-C, - 19% in Triglycerides, and - 53% in hs-CRP from baseline to week 52[44] Tolerability and Dosing - With one-step dose escalation in the Phase 2 study, the vomiting incidence was reduced and the discontinuation rate due to GI AEs was low at 8%[51] - Dose escalation significantly improves tolerability without compromising weight loss efficacy[9, 84] - Two-step dose escalation in the Phase 1 Low Dose Initiation study further reduced vomiting incidence with no discontinuation due to GI AEs[51] - In the Phase 1 Low Dose Initiation study, the mean baseline weight was 1006 kg[70]

Project Highlights - The Santa Cruz Copper Project has a low initial capital expenditure of $1.24 billion and low unit production costs of $1.32 per pound of copper[30] - The project anticipates a 23-year mine life with a 20,000 tonnes per day operation and conventional heap leach process achieving 92% copper recoveries[30] - During the first 15 years, the project expects to produce 72,000 tonnes of copper cathode per year with an average annual copper grade of 1.1%[30] - At the current COMEX copper price, the project boasts an after-tax Net Present Value (NPV) at an 8% discount rate of $1.9 billion and a 24% Internal Rate of Return (IRR)[30] Financial Metrics - At a copper price of $4.25 per pound, the after-tax NPV8% is $1.4 billion with a 20% IRR[30] - The project anticipates a life of mine revenue of $13.1 billion and after-tax free cash flow of $5.0 billion[31] - The capital intensity is projected at $17100 per tonne[31] Resources and Reserves - The project's probable reserves are estimated at 136 million tonnes with a total copper grade of 1.08%[45] - Indicated resources inclusive of mineral reserves for Santa Cruz and East Ridge contain 3.1 million tonnes of copper[62] - Inferred resources for Santa Cruz and East Ridge contain 0.6 million tonnes of copper[64] Operational Aspects - The surface infrastructure requires approximately 2,600 acres, which is 40% of the total land package[41] - The mine will access the top of mineral reserves at 310 meters beneath the surface via twin decline drifts measuring approximately 8 kilometers[50] - The study incorporates over 200 kilometers of longhole stoping and local drift-and-fill across 16 levels[50]

Xperi shareholders have the important opportunity to vote in support of Xperi management and incumbent directors as they continue to execute our revitalized strategy as a new independent company 2 Executing a Multi-Year Transformation to Drive Long-Term Shareholder Value M A Y 2 , 2 0 2 4 What is This Proxy Fight About? Xperi recommends that shareholders vote for the incumbent slate of directors at the 2024 Annual Meeting ▪ Xperi is a leading product-focused entertainment technology company, creating extrao ...

HNI Corporation Overview - HNI Corporation's TTM (Trailing Twelve Months) revenue is $2.53 billion[8] - HNI Corporation's TTM Non-GAAP EBITDA is $322.7 million[8] - HNI Corporation's 2024 Cash Dividends totaled $63.6 million[8] - HNI Corporation's five-year average free cash flow is $137 million, exceeding $3.00 per share[8] Workplace Furnishings Segment - HNI expects total savings of $80-$85 million compared to 2022, with $45-$50 million benefiting 2025 and 2026, equating to $0.70-$0.80 of incremental EPS[6,34] - HNI anticipates KII (Kimball International) synergies to reach $60 million by the end of 2026, more than double the initial projection from mid-2023[6,34] - HNI expects total net savings from the Mexico facility ramp to reach $20-$25 million by the end of 2026[6,34] - HNI expects total savings of $11 million by the end of 2026 from Hickory consolidation, which are included in KII synergies[6,34] - Industry shipments remain 12% below pre-COVID levels[57,58] - 2024 industry volume (adjusted for pricing actions/inflation) is approximately 35% below 2019 levels[57,58] Residential Building Products Segment - Approximately 20-25% of HNI's new home business flows through its vertically-integrated installing distribution model[67] - 61% of all mortgage rates are below 4%, creating a "lock-in" effect that is positive for future remodel/retrofit activity[75]

TERN-701 Opportunity - TERN-701 is a novel allosteric BCR-ABL TKI in Phase 1 studies, representing a new generation of therapies for CML with superior target coverage, improved kinase selectivity, and high potency against common mutations[16] - TERN-701 has the potential to transform the standard of care for CML by offering enhanced efficacy, minimal off-target activity, optimized dosing, and more rapid and deeper levels of response, potentially leading to treatment-free remission[16] - TERN-701 is expected to be the 2nd allosteric TKI to market, differentiating itself from asciminib[78] CML Market and Treatment Landscape - Approximately 10,000 new CML cases are diagnosed in the U S annually[10] - The U S CML prevalence is approximately 110,000 and is expected to triple by 2040[10] - Around 40% of CML patients switch therapy within 5 years due to intolerance or resistance[10] - About half of CML patients do not achieve deep molecular response (DMR) by 4 years after switching to a second treatment[10] - Allosteric inhibitors represent the latest evolution in CML treatment, with asciminib being the first approved allosteric BCR-ABL inhibitor[12] Clinical Development and Data Interpretation - Baseline BCR-ABL levels impact the speed and attainment of MMR in relapsed/refractory (R/R) CML patients; patients with baseline BCR-ABL of >10% had the lowest molecular response rates to asciminib in Phase 1[38, 42] - Terns' initial Phase 1 data for TERN-701 will comprise patients with shorter treatment duration compared to precedent initial Phase 1 data disclosures[64] - Interim dose escalation data for TERN-701, expected in December, will include an estimated 10-20 enrolled patients, with 5-10 patients having ≥3 months of treatment across at least 2 dose levels[66] Future Strategy - TERN-701 has broad anticipated opportunity across 1L and 2L, with the potential to split 1L allosteric share and capture 2G TKI intolerant/resistant patients[76, 77] - Subsequent readout in 2025 is anticipated to show 6-month data and inform potential registrational trial[79]

HB-200 Program and Clinical Trials - Hookipa Pharma's HB-200 is a targeted immunotherapy for HPV16+ cancers, with a pivotal Phase 2/3 trial expected to start in Q4 2024[14, 16] - The FDA has aligned on the pivotal Phase 2/3 design and protocol for HB-200, and the EMA has granted PRIME designation[16] - A Phase 1/2 study of HB-200 in recurrent/metastatic HPV16+ HNSCC showed promising antitumor activity as a monotherapy[25, 26] - The combination of HB-200 and pembrolizumab demonstrated a manageable safety profile, in line with monotherapy profiles[28, 30] - The Phase 2/3 trial will be a seamless study with approximately 250 patients, with a Phase 2 primary analysis expected in 2026 and a Phase 3 primary analysis in 2028[47, 48] Clinical Data and Efficacy - In patients with PD-L1 CPS ≥1, HB-200 + pembrolizumab showed an objective response rate (ORR) of 371% and a disease control rate (DCR) of 686%[32] - In the PD-L1 CPS ≥20 sub-population, the confirmed ORR was 529%, with a complete response (CR) rate of 176% and a DCR of 824%[37] - Preliminary progression-free survival (PFS) in the PD-L1 CPS ≥20 population was 163 months, and median overall survival (OS) was unreached, with 158% of subjects experiencing death events[42, 43, 44] - Neoadjuvant HB-200 plus chemotherapy showed an early efficacy signal with a deep response rate of 81% (17 of 21 patients)[51] Oncology Strategy and Market - Hookipa Pharma is pursuing a patient-centric oncology strategy, starting with HB-200 in head and neck cancer, with potential applicability to additional antigens and HPV16+ targets[55, 56]

High Grade, Long Life Copper Exposure in a Tier 1 Jurisdiction Investor Presentation April 2024 This presentation has been prepared by MAC and while believed to be accurate and reliable, MAC, nor any of its related bodies corporate, their respective directors, partners, employees or advisers or any other person (Relevant Parties), do not make any representations, warranties or undertakings, express or implied, as to the fairness, currency, accuracy, completeness or correctness of such information or any fur ...